Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Dibutyryl-cAMP: A Better Assay Control Strategy
2026-09-02
Dibutyryl-cAMP, sodium salt is more than a cAMP pathway agonist: it is a practical perturbation control for separating PKA signaling from tissue-specific biology. This article connects DBcAMP sodium salt workflow design with new lessons from tau research.
-
Ceftazidime in the Resistance Translation Era
2026-09-01
Ceftazidime remains a strategically useful third-generation cephalosporin for Gram-negative bacterial infection research, particularly when Pseudomonas biology, β-lactamase activity, and resistance transmission must be interpreted together. This article connects its cell-wall mechanism with recent carbapenemase surveillance and provides practical guidance for translational assay design.
-
Cy5 Maleimide in Condensate Imaging
2026-09-01
Cy5 maleimide enables site-specific protein labeling, but its value extends beyond conventional imaging. This article explains how non-sulfonated Cy5 maleimide can support charge-aware studies of α-synuclein condensates and improve interpretation of fluorescence partitioning assays.
-
Penicillin G Sodium in Cell Culture Workflows
2026-08-31
Penicillin G Sodium provides targeted protection against susceptible bacterial contaminants while preserving the interpretability of mammalian cell assays when used with appropriate controls. This guide translates a melanoma-cell workflow into practical preparation, optimization, troubleshooting, and infection-research decisions.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-31
A 2025 study found that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike-protein binding to host receptors, with particularly strong effects for shorter or N-terminally modified fragments. The work connects renin-angiotensin system peptide processing with a biochemical step relevant to viral entry, while its antibody-based design indicates that validation in cellular and physiological models is still needed.
-
Staurosporine: Interpreting Kinase-Driven Cell Death
2026-08-30
Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor used to connect kinase perturbation with apoptosis and tumor biology. This article explains how to interpret its effects mechanistically, design better assays, and avoid confusing a reproducible death phenotype with pathway-specific proof.
-
Ceftolozane/Tazobactam Dosing in P. aeruginosa
2026-08-29
Ruiz and colleagues used pharmacokinetic/pharmacodynamic simulation to test whether ceftolozane/tazobactam regimens achieve bactericidal exposure targets in Pseudomonas aeruginosa bacteremia across different levels of renal clearance. The analysis supports standard exposure for a 40% fT>MIC target but identifies 2 g of ceftolozane, administered by extended infusion, as the more reliable strategy for sustained 100% fT>MIC exposure in patients with high renal clearance.
-
Carbapenemase Gene Spread in CREC: Guangdong Study
2026-08-28
A 2025 BMC Microbiology study combined gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element analysis, and ERIC-PCR to investigate carbapenem-resistant Enterobacter cloacae across eight teaching hospitals. Its findings indicate that plasmid-associated blaNDM-1 and highly transferable resistance determinants may connect multidrug resistance with both horizontal gene transfer and clonal dissemination.
-
Apicidin Workflows for HDAC and Oocyte Assays
2026-08-28
Apicidin enables controlled interrogation of HDAC3-linked chromatin regulation, cancer-cell phenotypes, and reproductive toxicology. This guide connects biochemical potency with practical dosing, meiotic imaging, tumor-model context, and troubleshooting strategies.
-
From Nanovesicle Mechanism to Protein Evidence
2026-08-27
A translational framework for converting PD-L1 nanovesicle biology into reproducible protein-level evidence using customizable lysis and assay design.
-
Pitavastatin (NK-104): In Vitro Workflow Guide
2026-08-27
Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibition workflow for cellular cholesterol-synthesis assays, with a dossier benchmark of 5.8 nM in HepG2 cells. It is best used for controlled in vitro research, including cardiovascular and atherosclerosis research, and should not be treated as clinically or in vivo validated without additional evidence.
-
Penicillin G Sodium for Reproducible Cell Assays
2026-08-26
Learn how Penicillin G Sodium (SKU B1678) can help laboratories control susceptible bacterial contamination without obscuring interpretation of viability, proliferation, or cytotoxicity assays. This scenario-based guide connects published cell-culture practice with formulation, handling, controls, and vendor-selection considerations.
-
Ceftolozane/Tazobactam: Mechanism and Evidence
2026-08-26
The reference review evaluates ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination designed to address resistant Gram-negative pathogens. Its key contribution is the integration of mechanism, pharmacodynamics, susceptibility, clinical, and safety evidence, while also defining the renal and exposure-related considerations relevant to translational study design.
-
Ceftolozane/Tazobactam: Mechanism, PK, and Evidence
2026-08-25
The reference review explains why ceftolozane/tazobactam was developed as an antipseudomonal cephalosporin–β-lactamase inhibitor combination for resistant Gram-negative infections. Its main contribution is an integrated analysis linking PBP selectivity, β-lactamase activity, pharmacokinetic/pharmacodynamic targets, clinical indications, and safety considerations.
-
Murine RNase Inhibitor for RNA Workflows
2026-08-25
Murine RNase Inhibitor protects RNA in RT-PCR, cDNA synthesis, transcription, and labeling workflows where oxidation or low DTT can compromise conventional inhibitors. Its selective RNase A inhibition preserves RNA integrity without blocking RNase H, RNase T1, or other non-pancreatic nucleases.